このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Abliva 将来の成長

Future 基準チェック /06

Ablivaの収益は年間21.9%で減少すると予測されていますが、年間収益は年間122.5%で増加すると予想されています。EPS は年間4.2%で減少すると予想されています。

主要情報

-21.9%

収益成長率

-4.2%

EPS成長率

Biotechs 収益成長	39.9%
収益成長率	122.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	27 May 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

OM:ABLI - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3	N/A	N/A	N/A	1
12/31/2025	N/A	-146	-140	-139	1
12/31/2024	N/A	-128	-120	-119	1
3/31/2024	0	-98	-28	-27	N/A
12/31/2023	0	-96	-9	-8	N/A
9/30/2023	N/A	-88	-15	-15	N/A
6/30/2023	0	-80	-115	-114	N/A
3/31/2023	0	-79	-145	-144	N/A
12/31/2022	0	-85	-160	-160	N/A
9/30/2022	0	-105	-195	-194	N/A
6/30/2022	0	-114	-121	-120	N/A
3/31/2022	0	-124	-124	-123	N/A
12/31/2021	0	-123	-115	-114	N/A
9/30/2021	2	-100	-86	-84	N/A
6/30/2021	2	-75	-69	-68	N/A
3/31/2021	2	-65	-54	-53	N/A
12/31/2020	2	-60	-69	-68	N/A
9/30/2020	1	-74	-79	-77	N/A
6/30/2020	3	-79	-84	-82	N/A
3/31/2020	4	-80	-83	-80	N/A
12/31/2019	4	-77	-75	-72	N/A
9/30/2019	4	-65	-67	-63	N/A
6/30/2019	2	-64	-61	-57	N/A
3/31/2019	2	-69	-75	-72	N/A
12/31/2018	2	-68	-68	-64	N/A
9/30/2018	2	-68	-66	-62	N/A
6/30/2018	2	-66	-68	-64	N/A
3/31/2018	0	-63	-61	-57	N/A
12/31/2017	0	-67	N/A	-58	N/A
9/30/2017	0	-66	N/A	-60	N/A
6/30/2017	0	-87	N/A	-55	N/A
3/31/2017	0	-76	N/A	-55	N/A
12/31/2016	0	-70	N/A	-57	N/A
9/30/2016	N/A	-63	N/A	-62	N/A
6/30/2016	N/A	-83	N/A	-66	N/A
3/31/2016	3	-87	N/A	-59	N/A
12/31/2015	3	-90	N/A	-67	N/A
9/30/2015	4	-100	N/A	-52	N/A
6/30/2015	11	-49	N/A	-50	N/A
3/31/2015	8	-47	N/A	-49	N/A
12/31/2014	8	-43	N/A	-44	N/A
9/30/2014	7	-35	N/A	-47	N/A
6/30/2014	1	-38	N/A	-41	N/A
3/31/2014	6	-27	N/A	-31	N/A
12/31/2013	7	-22	N/A	-19	N/A
9/30/2013	8	-19	N/A	-18	N/A
6/30/2013	7	-16	N/A	-14	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABLI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ABLI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ABLI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ABLI来年は収益がないと予測されています。

高い収益成長: ABLI来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABLIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Abliva 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Abliva AB (Publ) Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease

New minor risk - Shareholder dilution

Abliva AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 46.093054 million.

Full year 2023 earnings released: kr0.09 loss per share (vs kr0.12 loss in FY 2022)

New minor risk - Share price stability

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Abliva AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

Abliva AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Abliva AB (publ) Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (publ), Annual General Meeting, May 23, 2024

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Chairman of the Board recently bought kr494k worth of stock

Abliva AB (Publ) Announces First Patient Dosed in the Falcon Study

Abliva AB (Publ) Announces Resignation of Edwin Moses as Director

Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333

No independent directors

Abliva AB (publ), Annual General Meeting, Apr 27, 2023

Abliva AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Director recently bought kr35m worth of stock

Abliva AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

No independent directors

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings: EPS misses analyst expectations

US Food and Drug Administration Approves Abliva's Investigational New Drug (IND) Application for KL1333

Third quarter 2021 earnings released: kr0.086 loss per share (vs kr0.03 loss in 3Q 2020)

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Abliva Reports Positive Clinical Phase 1A/B Results for KL1333 Including Signs of Efficacy in PMD Patients

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva Completes Phase Ia/Ib Study with KL1333

Full year 2020 earnings released: kr0.24 loss per share (vs kr0.45 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day low: kr0.74

Chief Executive Officer Erik Kinnmann has left the company

Abliva Announces CEO Changes, with Effect from February 3rd

New 90-day low: kr0.77

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Third quarter 2020 earnings released: kr0.03 loss per share

Abliva AB (publ) to Report Fiscal Year 2021 Results on Feb 22, 2022

New 90-day low: kr0.78

New 90-day low: kr0.91

Abliva AB Announces Resignation of Magnus Persson From Board of Directors

Earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘